Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease

Ajit Monteiro, Arthur J. Chang, R. Ross Welliver, Sarah Baron, Mark D. Hicar*

Department of Pediatrics, University at Buffalo, Buffalo, NY, USA

ARTICLE INFO

Keywords:
- Kawasaki disease
- Multisystem inflammatory syndrome in children
- SARS-CoV-2
- Coronavirus
- Cross-immunity
- Coronary aneurysms

ABSTRACT

Multisystem Inflammatory Syndrome in Children (MIS-C), a post infectious complication of SARS CoV-2 infection, shares enough features with Kawasaki Disease (KD) that some have hypothesized cross-coronavirus (CoV) immunity may explain the shared pathology. Recent studies have shown that humoral cross-reactivity of the CoVs, particularly of OC43, is focused on the S2 region of the Spike protein.

Due to efforts utilizing CoV S2 regions to produce a cross-CoV vaccine, we wished to assess SARS-CoV-2 S2 reactivity in children with KD and assess if cardiac involvement in KD correlated with S2 CoV antibody targeting. The presence of cross-reactivity does not distinguish KD from febrile controls and does not correlate with cardiac involvement in KD. These findings support that, in relation to cardiac vascular inflammation, vaccines targeting the S2 region appear to be a safe approach, but there is disparity in the ability of CoV species to raise cross-reactive S2 targeted antibodies.

1. Introduction

Cross-coronavirus (CoV) vaccines are being pursued, but lack of knowledge of immune related conditions related to SARS-CoV-2, such as Multisystem Inflammatory Syndrome in Children (MIS-C), necessitates caution. Class I fusion proteins, utilized in viral families Arenaviridae, Coronaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, and Retroviridae, form trimers that contain a region that facilitates recognition of the targeted host cellular receptor and a region that enables cell and viral membrane fusion. (Schibli and Weissenhorn, 2004). For Coronaviridae, the S2 region enables fusion and contains two heptad repeat (HR) regions that have significant alpha-helical structure (Monteiro et al., 2021). The S2 folds to approximate the alpha-helical HR regions to form a trimer of helical hairpins termed a six-helix bundle (6HB) (White et al., 2008), which is crucial for approximating the two membranes leading to fusion (Schibli and Weissenhorn, 2004; White et al., 2008; Eckert and Kim, 2001; Skehel and Wiley, 2000; Ding et al., 2017).

The common cold human CoVs (hCoVs) can be divided into alpha (CoV-229E and CoV-NL63) and beta (CoV-HKU1 and CoV-OC43). Cross-CoV humoral immunity has been demonstrated (Ng et al., 2020) and is likely explained by prior immunity to circulating hCoVs (Grifoni et al., 2020; Shroock et al., 2020). Pre-pandemic samples with detectable levels of SARS-CoV-2 reacting antibodies had higher levels of antibodies against the hCoV-OC43 S protein and specifically the S2 segment (Anderson et al., 2021a). Prior immunity to circulating hCoVs is boosted after SARS-CoV-2 infection (Anderson et al., 2021a). A number of studies suggest prior immunity to circulating hCoVs may contribute to SARS-CoV-2 neutralization (Dugas et al., 2021a; Galipeau et al., 2021). The cross reactivity between SARS-CoV-2 and other circulating hCoVs is predominantly based on S2 region cross-reactivity (Wolfe et al., 2020; Nguyen-Contant et al., 2020), including Cross-CoV neutralizing antibody responses (Jennewein et al., 2021). Studies have shown that the structure of the C-terminal HR region of the S2 region is particularly conserved among the CoV species (Xia et al., 2020). On comparative sequence analysis, hCoV-OC43 has significant homology in the S2 region in comparison to other hCoVs (Monteiro et al., 2021; Nguyen-Contant et al., 2020; Anderson et al., 2020; Beretta et al., 2020). A peptide fusion inhibitor developed from the OC43 hCoV CHR has even shown inhibition against other CoV species (Xia et al., 2019), including SARS-CoV-2 (Xia et al., 2020). Humoral immunity to OC43 in particular has been associated with potential cross-neutralization and improved clinical outcomes (Dugas et al., 2021a, 2021b).

Early reports noted the similarity of SARS-CoV-2 related MIS-C to Kawasaki Disease (KD) (Riphagen et al., 2020; Verdoni et al., 2020; Hennon et al., 2021). KD is a vasculitis and major cause of childhood acquired heart disease in the pediatric population. Epidemiological

* Corresponding author. University at Buffalo, 6072 UB CTRC, 875 Ellicott Street, Buffalo, NY, 14203, USA.
E-mail address: markhica@buffalo.edu (M.D. Hicar).

https://doi.org/10.1016/j.j.virol.2022.08.010
Received 25 April 2022; Received in revised form 17 August 2022; Accepted 22 August 2022
Available online 2 September 2022
0042-6822/© 2022 Elsevier Inc. All rights reserved.
patterns suggest KD is related to an infectious agent; however, the etiology remains unknown (McCrindle et al., 2017). Prior reports have suggested CoVs can cause KD (Shirato et al., 2014; Esper et al., 2005).

We have previously addressed whether targeting of the RBD epitope, full Spike protein, or nucleoprotein could explain the similar pathogenesis seen in children with KD and post-acute SARS-CoV-2 MIS-C. A number of prepandemic samples from febrile children had significant increase in binding to SARS-CoV2 nucleocapsid protein (NP) and Spike (S) antigens; however, cross-reactivity did not appear to be elevated in children with Kawasaki disease (Chang et al., 2020).

Recent studies suggest vaccine will prevent cases of MIS-C (Levy et al., 2022; Zambrano et al., 2022). Although MIS-C does not appear to be associated with immune reactivity to the Spike protein (Chang et al., 2020), the cases of post-vaccination myocarditis with the mRNA vaccines suggest that the platform plays a significant role in induction of these cases of post-vaccination myocarditis. As broad spectrum hCoV fusion inhibitors (Wang et al., 2021) and vaccine approaches (Jennewein et al., 2021) are targeting the S2 region and COVID-19-associated illnesses and vaccinations may be associated with myocarditis, we sought to further explore cross-CoV immunity in groups of children with KD and other febrile pediatric patients with a focus on the S2 region and association with cardiac complications.

2. Methods

2.1. Proteins utilized

Human expressed proteins of Receptor Binding Domain (hRBD; Synthetic construct SARS-CoV-2 RBD his gene; GenBank: MT380724.1) and Trimerized S (hTrimS; Synthetic construct SARS-CoV-2 ectoCSPP gene; GenBank: MT380725.1) were expressed utilizing expression vectors from Florian Kramer’s laboratory in 293 F cells following published protocol (Amanat et al., 2020). The sequence is based on the first published isolate Wuhan-Hu-1 (Wu et al., 2020). The following commercial reagents expressed in Baculovirus were obtained from Sino Biological: Nucleocapsid Protein (NP) (Cat # 40588-V08B), S Protein, S1+S2 ECD (Cat#40589-V08B1), SARS-CoV-2 S2 subunit (Cat # 40590-V08B), hCoV-OC43 whole S protein (Cat# 40607-V08B) and hCoV-OC43 S2 subunit (Cat# 40607-V08B1). The Sino Biological human expressed protein RBD (Cat#40592-V08H) was also used for comparison.

2.2. Patient cohorts

Plasma samples from inpatients with fever and respiratory distress who were tested and were SARS-CoV-2 polymerase chain reaction (PCR) positive were used as the positive control for normalization of ELISA results. These were collected with IRB approval (University at Buffalo (UB) STUDY00004340) utilizing State University of New York Research Seed Grant Program as previously described (Chang et al., 2020). Plasma samples from 123 febrile controls (FC) and 26 febrile children diagnosed with KD (UBKD), 24 of which had pre-IVIG samples, and their associated clinical information were collected under approval of the UB IRB STUDIES-00000126, 00002824 and 00005262 with funding support by the Wildermuth Memorial Foundation as previously described (Martin et al., 2018). During peripheral blood mononuclear cell (PBMC) isolation for a separate study, plasma was withdrawn and saved cooled in a −80 °C freezer and associated deidentified clinical information was retained. Additional serum samples (30 subjects with pre-treatment, post-treatment, and convalescent samples) were obtained through the Pediatric Heart Network and stored in the Kawasaki Disease Biorepository (KDB) at Boston Children’s Hospital (IRB X10-01-0308) collected for a prior study (Newburger et al., 2007). The subset of KDB subjects used herein met complete KD criteria and were treated with intravenous immunoglobulin (IVIG). For UBKD sample, the KD diagnosis was assigned if infectious disease consultation agreed with KD as likely diagnosis, KD was agreed by separate infectious disease specialist on post-hoc review, and patient received IVIG. Other clinical group final diagnoses were defined by post-hoc review of EMR documents including all available laboratories and follow-up assessments. Statistical analysis was performed using GraphPad Prism 9 and groups were compared with Wilcoxon ranked sum tests and Pearson R correlations.

Z scores were calculated using the downloadable Kobayashi Z-score Calculator available from http://raise.umin.jp/zsp/calculator/(Kobayashi et al., 2016) and the Boston Z-score calculator at https://zscore.chboston.org for both the UBKD and KDB cohorts for comparison. Briefly, patient height, weight, gender, and measured coronary arterial diameter for RCA, LMCA, LAD and LCx for the Kobayashi score were transcribed into appropriate columns in the calculator. Body surface area and Z scores for each coronary artery were then automatically calculated.

3. ELISA

The ELISA protocol used followed a recently published SARS-CoV-2 related protocol (Stadlbauer et al., 2020) with minor adjustments (use of Goat Anti-Human Ig-HRP (Southern Biotech) secondary and TMB Ultra (Thermo Fisher) as developer. Generally, 96-well ELISA plates were coated with proteins at 10 ng/well. Plates were then sealed and incubated overnight at 4 °C. Plates were washed three times with wash buffer (1x PBS, 0.05%Tween-20). All wells were then blocked with 100ul of 5% milk in PBS and incubated at room temperature for 1 h.
Plates were then aspirated and washed once with wash buffer. 50µl of
diluted plasma samples of 1:50 in 1% milk PBST were added to each well
and incubated at room temperature for 1 h. Plates were then aspirated
and washed three times. Goat Anti-Human Ig-HRP (Southern Biotech),
diluted in 1% milk in PBST, was added and incubated at room tempera-
ture for 1 h. Plates were then aspirated, washed three times, and
developed with TMB solution with acid stop prior to optical density
reading at 450 nm with background plate reading at 630 nm subtracted.
For disparate results, antigen ELISAs were run in triplicate with
outliers greater than 2-fold difference from average of other sample
results removed.

4. Results

4.1. Cross-reactivity to SARS-CoV-2 in prepandemic febrile children

Samples collected at UB from 2013 to 2018 were used to assess cross-
reactivity of circulating immunoglobulin. Of the 26 children with KD
enrolled (designated UBKD), the majority (18) fulfilled the diagnostic
criteria for complete KD and only two had significantly high Z scores of
coronary arteries on echocardiogram (Table 1). Antigen binding was
normalized to SARS-CoV-2 infected control samples on each plate to
facilitate intra-antigen and inter-antigen comparisons across plates. In
our initial study, cross-reactivity for NP was particularly evident in a
number of cross-reactive FC samples on NP, with 21 of 123 having over
10% above background and 3 of 123 over 20% of background in com-
parison to only one of our KD was above 10%. Likely this reflects a
number of infections with pre-pandemic circulating CoVs within our FC
cohort.

To explore differences in antigen recognition, we expressed tri-
merized S protein (hTrimS) in human cells (Amanat et al., 2020) to
compare to commercially available baculovirus expressed S constructs
(bS). In comparing the hTrimS to the bS constructs using pre-IVIG
samples, the bS constructs showed higher cross reactivity for both
clinical groups (KD p = 0.0007; FC p = 0.0011) on ranked-sum com-
parison. A subset of higher bS binding samples were used in the hTrimS
assays and are shown in direct comparison (Fig. 1B); only 1 of 40 showed
higher binding to hTrimS in normalized binding comparison. This is
consistent with previously published data that showed high specificity
of hTrimS binding using adult samples, and higher specificity of human
cell expressed proteins versus baculoviral proteins (Amanat et al., 2020).
As the trimerized protein showed less cross reactivity, this implies that
monomeric construct display epitopes that may be shielded when in
trimeric forms.

Similar binding was shown with KD samples (chRBD vs. hRBD; p
= 0.7866) on commercially available human expressed RBD (chRBD) and
human expressed RBD (hRBD) produced in our laboratory. Comparison
between those post-IVIG samples also showed no differences (chRBD vs.
hRBD; p = 0.9334). In comparison of the FC group, there did appear to
be higher cross-reactivity to the hRBD (chRBD vs. hRBD; p < 0.0001),
suggesting if there was bias introduced by our methods, it is in the

Table 1
Summary of clinical Aincal characteristics and Coronary Artery Z score

| Plasma | Age | Complete | Z > 2.5 |
|--------|-----|----------|---------|
| UBKD#  | (years) | KD? | KDB# | Serum | Age | Complete | Z > 2.5 |
| 01     | 5.8  | yes | 10021 | 4.9  | yes | LAD | LAD |
| 02     | 2.7  | no  | 10031 | 2.9  | yes |  |
| 03     | 2.3  | no  | 10045 | 3.2  | yes |  |
| 04     | 6.5  | yes | 10054 | 6.7  | yes |  |
| 05     | 4.1  | no  | 10060 | 2.5  | yes | LMCA | LMCA, RCA |
| 06     | 4.8  | yes | 10103 | 3.2  | yes | LMCA | LMCA, RCA |
| 07     | 6.8  | yes | 10112 | 4.6  | yes | LMCA |
| 08     | 2.4  | yes | 10140 | 0.3  | yes | LAD, LMCA, RCA | LAD, LMCA, RCA |
| 09     | 0.8  | yes | 10184 | 5.5  | yes |  |
| 10     | 1.8  | yes | 10196 | 7.8  | yes | LMCA |
| 11     | 1.7  | yes | 10262 | 6.8  | yes |  |
| 12     | 2.2  | yes | 10270 | 4.9  | yes |  |
| 13     | 4.4  | yes | 10298 | 4    | yes | LMCA |
| 14     | 6.9  | yes | 10351 | 0.2  | yes | LAD, LMCA, RCA | LAD, LMCA, RCA |
| 15     | 4.5  | no  | 10369 | 2.8  | yes | LCA, LMCA, RCA | LAD, RCA, LAD |
| 16     | 3.3  | no  | 10376 | 6    | yes | LAD |
| 17     | 1.9  | no  | 10396 | 1.5  | yes | RCA |
| 18     | 2.4  | yes | 10397 | 1    | yes |  |
| 19     | 1.0  | no  | 10400 | 1.1  | yes | LAD, LMCA |
| 20     | 3.3  | yes | 10442 | 0.2  | yes | LAD, LCA, LMCA, RCA | LAD, LMCA, RCA |
| 21     | 6.9  | yes | 10450 | 3.8  | yes | LAD |
| 22     | 1.6  | yes | 10477 | 4.1  | yes | LMCA |
| 23     | 2.5  | yes | 10515 | 4.5  | yes |  |
| 24     | 1.0  | yes | 10553 | 4    | yes |  |
| 25     | 4.5  | yes | 10557 | 5.5  | yes | LAD, LMCA, RCA | LAD, LMCA |
| 26     | 1.3  | no  | 10560 | 4.8  | yes | LMCA |

Kawasaki Disease: KD; left anterior descending- LAD; left circumflex artery- LCA, left main coronary artery- LMCA; right circumflex artery- RCA.
opposite direction to the results seen for S comparison. Administration of IVIG to patients led to increased reactivity in ELISAs. All comparisons of sample cohorts pre-IVIG and post-IVIG were significant to varying degrees (NP $p < 0.0001$; chRBD $p = 0.003$; hRBD $p = 0.0160$; bS $p < 0.0001$; hTrimS $p = 0.0002$).

4.2. SARS CoV S2 region targeting

We explored cross-reactivity of SARS-CoV-2 concentrating on the S2 region and utilizing OC43 to confirm this cross-reactivity in the pre-pandemic plasma samples. We obtained baculovirus expressed constructs of the S of OC43 (OC43-bS), and bS2 regions of OC43 (OC43-bS2) and SARS-CoV-2 (bS2). Sequence comparison of the OC43 S2 region to SARS-CoV-2 shows 43% identity. A number of samples from both FC and KD had higher immunoglobulin binding to recombinant bS2 compared to bS, however, comparison of bS to bS2 binding within either FC or KD groups was not statistically significant (Fig. 2A). The interrogation of OC43 antigens showed a number of samples with high normalized binding, which is consistent with the commonality of OC43 infection in this age group and inclusion of humoral immune responses to common hCoV antibodies in pooled IVIG. Although a number of samples were higher in convalescence, as a whole, these levels were not consistent with seroconversion against any of the antigens tested.

To explore immunoglobulin cross-reactivity to the SARS-CoV-2 S2 regions, we grouped plasma samples (FCs and KD) and the serum KD samples and looked at higher cross-reactive samples by defining high cross-reaction by being $>1$ standard deviation from the mean (Fig. 2B). For the plasma samples (bS2 sample mean 7.84, standard deviation 14.21, so $>22.05$, 12 samples qualified; and OC43 bS2 sample mean 20.76, standard deviation 21.50, so $>42.26$, 22 samples qualified). Reactivity of samples with high binding ($>1$ SD) to SARS-CoV-2 S2 also generally showed high binding to OC43 S2 (t-test was not significant), but in comparison to all high cross-reactive to OC43 S2 samples, few bound to the SARS-CoV-2 S2 (p $>0.0001$). This non-reciprocal cross-reactivity implies that OC43 reactivity contributes to most of the SARS-CoV-2 cross-reactivity shown in the pre-pandemic samples. This is consistent with other literature regarding cross reactivity of the S2 region that contributes to Spike reactivity (Wolfel et al., 2020; Nguyen-Contant et al., 2020).
4.3. Additional cohort confirms cross-reactivity post-IVIG in children with KD

To confirm these findings, we obtained serum samples from a cohort of 30 children with KD (KDB cohort), all with complete KD, with serial pre-IVIG, post-IVIG, and convalescent samples (Table 1). Again, administration of IVIG to patients led to increased reactivity in ELISAs. Post IVIG generally showed increased reactivity (Fig. 3) similar to what is shown in Fig. 1, with many samples showing cross-reactive bS protein targeting. Again, All comparisons of sample cohorts pre-IVIG and post-IVIG were significant to varying degrees (chRBD p = 0.0002; hRBD p = 0.0209; bS p = 0.0026; NP p < 0.0001).

On limited sample testing, we once again saw less binding to hTrimS compared to bS protein (see Supplemental Fig. 1). This cohort also showed high specificity of the hRBD produced protein, but one individual (sample 5, cohort #10376) had high reactivity to all commercial reagents, including chRBD.

Consistent with the plasma pediatric samples, many samples in the KD serum cohort showed immunoglobulin binding above background to OC43 antigens (Fig. 4). In comparison of higher SARS-CoV-2 bS2 cross-reactive and lower cross-reactive samples, the majority of those that had high cross S2 reactivity (8) had both high OC43-bS and OC43-bS2 region binding (Fig. 4A). Of those that had lower bS2 reactivity, a minority of samples showed OC43-bS and OC43-bS2 reactivity. This supports that OC43 immunity to the S2 region can also target SARS-CoV-2 S2. Once again, the post-IVIG samples (open circles) saw increases in OC43 binding in both subsets, which was particularly pronounced for the low SARS-CoV-2 cross-reactive subsets (Fig. 4A and B). These increases in cross-reactions were less pronounced in the convalescent samples suggesting that none of these cases of KD were due to OC43 infection.

To explore a role for potential aberrant coronavirus immune response that would explain aneurysms seen in MIS-C cases, we then correlated specific antigen targeting with presence of aneurysms in the prepandemic KD serum samples. With multiple comparisons using four different antigens, a conservative p value was set at 0.0125 using Bonferroni correction. Pearson correlations of the CoV spike antigens (bS and bS2) were all not significant. The strongest correlations (R = 0.36) were with OC43 bS antigen reactivity and Z score of the LAD (Boston score p = 0.05, Kobayashi score p = 0.054). SARS-CoV-2 bS and Z scores of LAD had negative R values and OC43 bS2 had R = 0.18 with p = 0.33 with both scoring systems. We also analyzed cardiac involvement using Z score cutoffs of both 2 and 2.5 for both Kobayashi (19 and 12 with cardiac involvement) and Boston scoring systems (11 and 8 with cardiac involvement) as detailed in Table 1. Generally, there were no statistically significant differences in antigen targeting between those that had aneurysms and those without aneurysms, although there was a trend toward higher cross-reactivity negatively correlating with aneurysm formation (Fig. 4C).

5. Discussion

As vaccines are being pursued that target the S2 region, knowledge of cross-reactive immunity to this region is needed. Samples from children are ideal to pursue such studies as they are more likely to have had recent exposures to a variety of circulating CoV species. Our study shows non-reciprocal immunity to the S2 region, suggesting that the vaccines targeting the S2 region may have different immune responses dependent on the chosen immunogen. However, immunity to this region does not appear to correlate with any known cardiac issue, supporting the safety of development of such vaccines.

The S2 region of CoVs has a number of traits that are enticing for therapeutic development and vaccine targeting. The S2 region is important in membrane fusion (Anderson et al., 2020; Xia et al., 2019). Amongst the human CoVs, the S2 region has the most sequence overlap (Nguyen-Contant et al., 2020; Beretta et al., 2020), and has been implicated in cross-CoV humoral immunity between the SARS-CoV-2...
and other hCoVs, particularly hCoV-OC43 (Anderson et al., 2021b). Peptide based fusion inhibitors, similar to enfuvirtide used for HIV (Monteiro et al., 2021), are being developed for hCoVs. Crystal structures indicate that OC43 derived EK1 can form a stable 6HB structure with both short alpha-hCoV and longer beta-hCoV NHRs, and can interfere in SARS-CoV-2 infection (Xia et al., 2019). Cross-reactive antibody responses to this region are being identified (Shiakolas et al., 2021). Although almost all the neutralizing antibodies of significance target the RBD (Liu et al., 2020; Rogers et al., 2020; Robbiani et al., 2020; Zost et al., 2020), including the majority of the cross-CoV antibodies, there are rare cross-CoV neutralizing antibodies targeting the S2 region (Jennewein et al., 2021).

This study also highlights that the use of IVIG may lead to increased reactivity in immunoglobulin ELISAs. In our study, prepandemic IVIG formulations have minor cross-reactive binding to SARS-CoV-2 antigens, and this likely reflects hCoV cross-immunity as previously noted (Diez et al., 2020). As a majority of the UBKD post-IVIG samples were collected near day ten, we would have expected more significant elevation if this post-IVIG increase was from seroconversion. In both UBKD and KDB cohorts, we did not see evidence of group seroconversion (sustained rise in convalescent samples), although it could not be discounted completely for individual samples.

This study has also has implications for commercial immunoassay development. A number of assays are available to assess clinical post-vaccine S protein targeting. Although most show high specificity, studies have lacked adequate pediatric samples. During the initial description of SARS-CoV-2 human expressed S constructs, specificity of samples was addressed using the alpha-CoV NL63 using solely adult sample (Amanat et al., 2020). There are significant structural differences between the alpha and beta CoVs, with beta-CoVs having shorter HR regions. Tests that relied on fuller regions of S had high specificity, but these were on cohorts that were solely COVID-19 samples lacking negative controls (National and S.-C.- S.A.E.G., 2020; Simanek et al., 2021; Baro et al., 2021), and rapid test were less specific (Wakita et al., 2021). A recent cohort of infants with PCR confirmed hCoV infections showed targeting to SARS-CoV-2 S2 was increased in samples from infants PCR positive for HKU1 and OC43, although overall they concluded that cross-reactivity was rare (Zar et al., 2021). Secondly, this study shows disparity in antigen reactivity from method of production. Binding to the human expressed trimeric S protein (hTrimS) construct was more specific than monomeric baculovirus (bS) expressed proteins. Likely, monomers present a number of epitopes that are not available on trimeric forms, which is well known for other class I fusion proteins such as HIV (Hicar et al., 2016a, 2016b). Differential his tagging of or difference in glycosylation, a known confounder with baculovirus expression, may also contribute to this difference. This is consistent with prior publications on similar constructs (Amanat et al., 2020). There were also some disparate results on samples with commercially available RBD (chRBD) and expressed RBD. It was intriguing that there was one individual with major disparity between chRBD and hRBD binding (sample 5). On sequence comparison, both of these RBD constructs contained the same S sequence and both are His-tagged, so this differential binding does not have an obvious explanation. Notably, the new variants of concern were not used for any of our assays (Variants of concern, 2021).

6. Conclusions

These findings support that, in relation to cardiac vascular inflammation, vaccines targeting the S2 region appear to be a safe approach, but there is hCoV species disparity in the ability to raise cross-reactive S2 targeted antibodies.
Statement of financial support

This work was supported by grants from the Office of Research and Economic Development State University of New York 2020 Research Seed Grant Program, the Wildermuth Memorial Foundation (USA) through Varity, the Children’s Charity of Buffalo & Western New York (USA), and by NIH R01 AI 12519-01. The authors have no financial relationships relevant to this article to disclose.

CRediT authorship contribution statement

Ajit Monteiro: Writing – original draft. Data curation, Writing – review & editing, drafted the initial manuscript, acquired data, and reviewed and revised the manuscript. Arthur J. Chang: Data curation, Writing – review & editing, acquired data, and reviewed and revised the manuscript. Sarah Baron: Data curation, Writing – review & editing, acquired data, and reviewed and revised the manuscript. R. Ross Welliver: Data curation, Writing – review & editing, acquired data, and reviewed and revised the manuscript. Mark D. Hicar: Conceptualization, Data curation, Writing – review & editing, conceptualized and designed the study, coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. All authors declare no competing interests. All authors attest they meet the ICMJE criteria for authorship.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mark D Hicar reports financial support was provided by National Institutes of Health. Mark D Hicar reports financial support was provided by Wildermuth Memorial Foundation.

Acknowledgements:

We thank Dr. Brian McCrindle for coordinating access to samples, and Dr. MaryBeth Son and Dr. Jane Newburger for coordinating access to samples and for their comments on this manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.virol.2022.08.010.

References

Amanat, F., et al., 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26 (7), 1033–1036.
Anderson, E.M., et al., 2020. Seasonal Human Coronavirus Antibodies Are Boosted upon SARS-CoV-2 Infection but Not Associated with Protection. medRxiv.
Anderson, E.M., et al., 2021a. Human coronavirus antibodies from COVID-19 show weak cross-reactivity in quaternary epitope targeting antibodies containing large numbers of somatic mutations. Mol. Immunol. 70, 94–103.
Beretta, A., Cranage, M., Zipeto, D., 2020. Is cross-reactive immunity triggering COVID-19 pandemic evolves. Prog. Pediatr. Cardiol., 101407.
Chang, A.J., et al., 2020. Serum responses of children with Kawasaki disease against SARS-CoV-2 spike. PLoS One 11 (7), e0158861.
Chang, A.J., et al., 2020. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Rep. 36 (2), 1095353.
Derij, J.M., Romero, C., Gajardo, R., 2020. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigen. J. Infec. Dis. 39 (11), e366–e367.
Dier, J.M., Romero, C., Gajardo, R., 2020. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigen. Immunotherapy 12 (8), 571–576.
Ding, X., et al., 2017. Enfuvirtide (T20)-Based lipopeptide is a potent HIV-1 cell fusion inhibitor: implications for viral entry and inhibition. J. Virol. 91 (18).
Dugas, M., et al., 2021a. Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1). Int. J. Infect. Dis. 105, 304–306.
Eckert, D.M., Kim, P.S., 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777–810.
Esper, F., et al., 2005. Association between a novel human coronavirus and Kawasaki disease. J. Infect. Dis. 191 (4), 499–502.
Galpeau, Y., et al., 2021. Relative ratios of human seasonal coronavirus antibodies predict the efficiency of cross-neutralization of SARS-CoV-2 spike binding to ACE2. EBioMedicine 74, 103700.
Grifoni, A., et al., 2020. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe 24 (7), 671–680 e2.
Homan, C., et al., 2021. COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines; revisiting the Western New York approach as the pandemic evolves. Prog. Pediatr. Cardiol., 101407.
Hicar, M.D., et al., 2016a. Human antibodies that recognize novel immunodominant quaternary epitopes on the HIV-1 env protein. PLoS One 11 (7), e0158861.
Hicar, M.D., et al., 2016b. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations. Mol. Immunol. 70, 94–103.
Jennwewin, M.F., et al., 2021. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Rep. 36 (2), 1095353.
Kobayashi, T., et al., 2016. A new Z score curve of the coronary arterial internal diameter using the Lambda-Mu-Sigma method in a pediatric population. J. Am. Soc. Echocardiogr. 29 (8), 794–801 e29.
Levy, M., et al., 2022. Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. JAMA 327 (3), 281–283.
Liu, L., et al., 2020. Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. Nature 584 (7821), 450–456.
Martin, M., Wroniak, B.H., Hicar, M., 2018. Suppressed plasmablast responses in febrile infants, including children with Kawasaki disease. PLoS One 13 (3), e0193539.
McCrindle, B.W., et al., 2017. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American heart association. Circulation 135 (17), e927–e999.
Monteiro, A.Y., K.O, A., Hicar, M.D., 2021. Peptide-based fusion inhibitors for preventing the six-helix bundle formation of class I fusion proteins: HIV and beyond. Curr. HIV Res. 19 (6), 465–475.
National, S-C-S.A.E.G., 2020. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect. Dis. 20 (12), 1390–1400.
Newburger, J.W., et al., 2007. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N. Engl. J. Med. 356 (7), 663–675.
Ng, K.W., et al., 2020. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370 (6522), 1339–1342.
Nguyen-Contant, P., et al., 2020. S-protein reactive IgM and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit. mBio 11 (5).
Oster, M.E., et al., 2022. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 327 (4), 331–340.
Riphagen, S., et al., 2020. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 395 (10237), 1607–1608.
Rohblatt, D.F., et al., 2020. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584 (7821), 437–442.
Rogers, T.F., et al., 2020. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369 (6506), 956–963.
Schiemann, W., Weisenthal, M., 2004. Class I and class II viral fusion protein structures reveal similar principles in membrane fusion. Mol. Membr. Biol. 21 (6), 361–371.
Shikolos, A.R., et al., 2021. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell. Rep. Med. 2 (6), 100313.
Shirato, K., et al., 2014. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. J. Med. Virol. 86 (12), 2146–2153.
Shrock, E., et al., 2020. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science 365(6450), 370.
Simanek, V., et al., 2021. Five commercial immunoassays for SARS-CoV-2 antibody determination and their comparison and correlation with the virus neutralization test. Diagnostics 11 (4).
Skelch, J.J., Wiley, D.C., 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531–569.
Sobotta, A., et al., 2021. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr. Protoc. Microbiol. 57 (1), e109.
Studbauer, D., et al., 2020. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr. Protoc. Microbiol. 57 (1), e109.
Verdoni, L., et al., 2020. Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. PLoS One 16 (2), e0246536.
Wang, X., et al., 2021. Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. Protein Cell 12 (2), 84–96.
Wolfel, R., et al., 2020. Virological Assessment of Hospitalized Patients with COVID-19. Nature.
Wu, F., et al., 2020. Author Correction: a new coronavirus associated with human respiratory disease in China. Nature 580 (7803), E7.
Xia, S., et al., 2019. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci. Adv. 5 (4), eaav4580.
Xia, S., et al., 2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 30 (4), 343–355.
Zambrano, L.D., et al., 2022. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 Years - United States, July-December 2021. MMWR Morb. Mortal. Wkly. Rep. 71 (2), 52-58.
Zar, H.J., et al., 2021. Antibodies to seasonal coronaviruses rarely cross-react with SARS-CoV-2: findings from an African birth cohort. Pediatr. Infect. Dis. J. 40 (12), e516-e519.
Zost, S.J., et al., 2020. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat. Med. 26, 1422-1427.